小细胞肺癌药物治疗进展

小细胞肺癌（small cell lung cancer，SCLC）约占肺癌患者的13% 。与非小细胞肺癌相比具有早期转移倾向及对一线细胞毒性化疗药物敏感的特点。目前的治疗方式包括手术、胸部及脑部放疗和化疗。以铂类联合依托泊苷为标准一线化疗，治疗后复发率较高。拓扑替康单药为标准二线化疗，新型的靶向和免疫治疗等疗效均欠佳。因此小细胞肺癌的治疗亟待有新的突破。 

Advances in chemotherapy of small cell lung cancer

Small cell lung cancer (SCLC) accounts for about 13%of lung cancer. SCLC exhibits an early metastatic potential and sensitivi-ty to first-line cytotoxic chemotherapy compared with non-small cell lung cancer. Current treatments include surgery, radiotherapy, and chemotherapy. Platinum plus etoposide is viewed as the standard first-line chemotherapy. However, recurrence rate of cancer af-ter platinum plus etoposide chemotherapy is high. Topotecan monotherapy is the standard second-line chemotherapy. Meanwhile, novel targeted immunotherapy showed poor effects. Hence, new breakthroughs in the treatment of SCLC are urgently needed.